About CBR

Founded in 1992, CBR is the largest private newborn stem cell bank in the world, helping parents store more than 925,000 cord blood and cord tissue samples for their children.¹³⁸ CBR is dedicated to advancing the clinical application of cord blood and cord tissue stem cells by partnering with institutions to establish FDA-regulated clinical trials for conditions that have no cure today.

CBR has helped more than 600 families use their cord blood stem cells for established and experimental medical treatments — more than any other family cord blood bank.¹³⁸ CBR's goal is to expand the potential scope of newborn stem cell therapies that may be available to patients and their families.

CBR is part of the Generate Life Sciences (Generate) family of brands, a life sciences company helping to grow and protect families through reproductive, newborn stem cell, genetic screening, medical device, and healthcare technology services. Generate serves families from preconception to post-birth.

CBR is headquartered in Los Angeles, California. CBR's 80,000 square foot laboratory is located in Tucson, Arizona.

Cord Blood Registry is a registered trademark of CBR Systems, Inc.

CBR maintains standards for cellular therapy services through AABB accreditation, FDA-registration, and CLIA certification.

CBR has the longest history of accreditation with the AABB and the company's quality standards have been recognized through ISO 9001:2015 certification — the global business standard for quality.

A pioneer in newborn stem cell collection and cryopreservation, CBR believes in the power of newborn stem cells to improve lives today and their potential to revolutionize treatment for many conditions in the future.

CBR is the first family newborn stem cell bank to partner with leading research institutions to establish FDA-regulated clinical trials exploring the potential regenerative ability of stem cells to help treat conditions that have no cure today, including: acquired hearing loss, autism, cerebral palsy, and pediatric stroke.¹³⁸ In fact, 80% of the stem cell units released by CBR have been used for experimental regenerative therapies — more than any other family cord blood bank in the world.

CBR developed a crush-resistant, temperature protected, and electronically tracked kit that actively transforms into a cube to encase the blood and/or tissue collection, helping to ensure that it is protected and delivered safely. On average, the transport time from the hospital to CBR's lab is 19 hours. CBR processes cord blood using the AutoXpress® Platform* (AXP® II processing) — a fully automated, functionally closed stem cell processing technology. AXP®II has consistently higher published CD34+ recovery rates than other processing methods..^1-3,8

^{*AXP® II processing and AutoXpress are registered trademarks of ThermoGenesis Corp.}